ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) was the target of some unusual options trading on Monday. Stock investors acquired 30,842 call options on the company. This is an increase of 64% compared to the average daily volume of 18,768 call options.
ImmunityBio Trading Up 0.8%
NASDAQ:IBRX traded up $0.07 during midday trading on Monday, reaching $8.51. The company had a trading volume of 10,394,602 shares, compared to its average volume of 20,837,396. The firm has a market capitalization of $9.02 billion, a price-to-earnings ratio of -8.77 and a beta of 0.04. The stock’s fifty day simple moving average is $7.84 and its 200-day simple moving average is $7.80. ImmunityBio has a 12-month low of $1.95 and a 12-month high of $12.43.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The company had revenue of $51.24 million during the quarter, compared to analysts’ expectations of $49.70 million. As a group, sell-side analysts expect that ImmunityBio will post -0.44 EPS for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on ImmunityBio
Insiders Place Their Bets
In related news, Director Christobel Selecky sold 159,478 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $9.02, for a total transaction of $1,438,491.56. Following the transaction, the director owned 35,064 shares of the company’s stock, valued at approximately $316,277.28. This represents a 81.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 131,210 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total value of $1,246,495.00. Following the transaction, the director owned 125,386 shares of the company’s stock, valued at $1,191,167. This trade represents a 51.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 291,688 shares of company stock valued at $2,693,987 over the last ninety days. Insiders own 66.10% of the company’s stock.
Hedge Funds Weigh In On ImmunityBio
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sigma Planning Corp raised its stake in ImmunityBio by 7.3% in the second quarter. Sigma Planning Corp now owns 19,015 shares of the company’s stock valued at $166,000 after buying an additional 1,300 shares in the last quarter. Archer Investment Corp boosted its position in shares of ImmunityBio by 67.1% during the 1st quarter. Archer Investment Corp now owns 5,872 shares of the company’s stock worth $45,000 after acquiring an additional 2,358 shares in the last quarter. Winning Points Advisors LLC increased its holdings in shares of ImmunityBio by 0.4% in the 2nd quarter. Winning Points Advisors LLC now owns 726,258 shares of the company’s stock valued at $2,287,000 after acquiring an additional 2,685 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of ImmunityBio by 18.3% in the 1st quarter. Principal Financial Group Inc. now owns 19,710 shares of the company’s stock valued at $151,000 after acquiring an additional 3,050 shares during the last quarter. Finally, Markowski Investments acquired a new stake in shares of ImmunityBio during the 2nd quarter worth about $29,000. 8.58% of the stock is owned by institutional investors and hedge funds.
About ImmunityBio
ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies and other treatments designed to activate the immune system against cancer and infectious diseases. The company’s platform combines biologics, cell therapies, vaccines and other approaches intended to generate durable immune responses.
Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.
Featured Stories
- Five stocks we like better than ImmunityBio
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
